SEHK:512Pharmaceuticals
The Bull Case For Grand Pharmaceutical Group (SEHK:512) Could Change Following Neffy Nasal Adrenaline Approval In China
Grand Pharmaceutical Group has announced that Neffy®, the world’s first adrenaline nasal spray, has obtained drug registration approval from China’s National Medical Products Administration for emergency treatment of type I allergic reactions in adults and children over 30kg, with exclusive commercialization rights in Mainland China and planned localized production within 24 months.
This marks the first non-injectable adrenaline treatment approved in China, potentially broadening real-world...